# A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

> **NCT01359852** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [11C] JNJ-42491293
- **DRUG:** [11C] JNJ-42491293 + JNJ-40411813
- **DRUG:** [11C] JNJ-42491293 + JNJ-40411813
- **DRUG:** [11C] JNJ-42491293

## Key facts

- **NCT ID:** NCT01359852
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359852, "A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01359852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*